Abstracts tagged "Cardiovascular disease"

Abstract Number: 1512 • 2018 ACR/ARHP Annual Meeting
Reduction in Power Doppler Ultrasound Score with Tocilizumab Treatment Associates with Improvement in the Protective Profile of HDL in Patients with Rheumatoid Arthritis
Christina Charles-Schoeman¹, Gurjit Kaeley², Jennifer Wang³, Ani Shahbazian³, Jenny Brook⁴, David Elashoff⁴ and Veena K. Ranganath⁵, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²UF Health Jacksonville, Jacksonville, FL, ³University of California, Los Angeles, Los Angeles, CA, ⁴Department of Medicine Statistics Core, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵1000 VETERAN BLVD., RM 32-59, UCLA, Los Angeles, CA
Background/Purpose: Musculoskeletal ultrasound (MSUS) can detect synovitis by Power doppler (PDUS) and can predict erosive progression on xrays in rheumatoid arthritis (RA) patients. We previously…
Abstract Number: 1881 • 2018 ACR/ARHP Annual Meeting
Discovery and Validation of Novel Disease Subsets in 806 Patients with Takayasu’s Arteritis across Four International Cohorts
Ruchika Goel¹, Katherine B. Gribbons², Kathleen Maksimowicz-McKinnon³, Gary S. Hoffman⁴, Sathish Kumar⁵, George Joseph⁶, Raheesh Ravindran⁷, Aswin Nair⁸, David Cuthbertson⁹, Simon Carette¹⁰, Nader A. Khalidi¹¹, Curry L. Koening¹², Carol Langford¹³, Carol A. McAlear¹⁴, Paul A. Monach¹⁵, Larry W. Moreland¹⁶, Christian Pagnoux¹⁷, Philip Seo¹⁸, Antoine G. Sreih¹⁹, Kenneth J. Warrington²⁰, Steven R. Ytterberg²⁰, Peter A. Merkel²¹, Debashish Danda²² and Peter C. Grayson², ¹Rheumatology, Christian Medical College, Vellore Tamilnadu, India, ²National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, ³Rheumatology, Henry Ford Hospital, Detroit, MI, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵Child Health, Christian Medical College, Vellore, India, ⁶Cardiology, Christian Medical College, Vellore, India, ⁷Department of Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India, ⁸Clinical Immunology and Rheumatology, Christian Medical College, Vellore, India, ⁹Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ¹⁰Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Rheumatology, McMaster University, Hamilton, ON, Canada, ¹²Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹³Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ¹⁴Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁵Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁶Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁷Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹⁸Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²⁰Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ²¹University of Pennsylvania, Philadelphia, PA, ²²Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by variable patterns of damage throughout the large arteries. This study aimed to develop and validate a novel disease…
Abstract Number: 2814 • 2018 ACR/ARHP Annual Meeting
Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Fenglong Xie¹, Lang Chen¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) has been associated with reduced risk for cardiovascular disease (CVD) in several studies conducted among rheumatoid arthritis (RA) patients never exposed to…
Abstract Number: 505 • 2018 ACR/ARHP Annual Meeting
Impact of Biological Treatment on Left Ventricular Regional Dysfunction in Rheumatoid Arthritis Patients Determined with Global Circumferential and Longitudinal Strain Values Using Cardiac Magnetic Resonance Imaging
Isamu Yokoe^1,2, Hitomi Kobayashi³, Yasuyuki Kobayashi⁴, Natsumi Ikumi³, Atsuma Nishiwaki⁵, Kaita Sugiyama⁶, Yosuke Nagasawa⁶, Takamasa Nozaki⁶, Noboru Kitamura² and Masami Takei², ¹Rheumatology, Kyoundo Hospital, Sasaki Institute, Tokyo, Japan, ²Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁴Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ⁵Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁶Nihon University School of Medicine, Tokyo, Japan
Background/Purpose: Congestive heart failure (CHF) is a major contributor to morbidity and mortality in patients with rheumatoid arthritis (RA). Myocardial disease is typically clinically silent,…
Abstract Number: 805 • 2018 ACR/ARHP Annual Meeting
Diastolic Dysfunction in Scleroderma: An Investigation into Associated Risk Factors and Impact on Survival
Alicia M. Hinze^1,2, Laura K. Hummers¹, Fredrick M. Wigley¹, Monica Mukherjee³ and Ami A. Shah¹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Scleroderma heart disease often goes unrecognized until severe clinical manifestations are present. Diastolic dysfunction (DD) may identify patients at risk for cardiac complications by…
Abstract Number: 1565 • 2018 ACR/ARHP Annual Meeting
Comorbidity Burden in Primary Sjögren’s Syndrome: A Long-Term Observation in Clinical Practice
Chiara Baldini¹, Francesco Ferro¹, Nicoletta Luciano¹, Emanuele Calabresi¹, Antonella Cecchettini², Marta Mosca¹, Enzo Grossi¹ and Stefano Bombardieri¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²IFC, CNR, Pisa, Italy
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a complex disorder that may affect any organ and system. In this new era of personalized medicine, a growing…
Abstract Number: 1913 • 2018 ACR/ARHP Annual Meeting
Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis
Saba Ziaee¹, Siri Kunchakarra², Cara Joyce³, Mark Rabbat⁴ and Rochella A. Ostrowski⁵, ¹Loyola University Medical Center, Maywood, IL, ²Cardiology, Loyola University Medical Center, Maywood, IL, ³Clinical Research Office, Loyola University Medical Center, Maywood, IL, ⁴Division of Cardiology, Loyola University Medical Center, Maywood, IL, ⁵Division of Rheumatology, Loyola University Medical Center, Maywood, IL
Background/Purpose: Cardiac sarcoidosis has been noted in 2-7% of patients with sarcoidosis. However, the incidence is >20% based on necropsy data. Given the poor yield…
Abstract Number: 2817 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro² and Kaleb Michaud^1,2, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Cardiovascular disease (CVD) represents the leading cause of death in RA, accounting for ~50% of excess mortality. Disease activity, strongly linked to CVD, has…
Abstract Number: 145 • 2017 ACR/ARHP Annual Meeting
Cause-Specific Mortality in a Large Population-Based Cohort of Rheumatoid Arthritis Patients in Italy
Francesca Ometto¹, UGO FEDELI², ELENA SCHIEVANO², Costantino Botsios³, MARIA CHIARA CORTI² and Leonardo Punzi⁴, ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, PADOVA, Italy, ²Epidemiological Department, Veneto Region, VENETO, Italy, ³Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ⁴Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Background/Purpose: Studies on mortality in RA from Italy are completely lacking. The aim of our study was to investigate cause-specific mortality in RA subjects living…
Abstract Number: 1088 • 2017 ACR/ARHP Annual Meeting
Staff Protocol in Rheumatology Clinics Reduces Population-Level Rate of High Blood Pressure
Christie M. Bartels¹, Edmond Ramly², Emmanuel Sampene³, Diane Lauver⁴, Patrick McBride⁵ and Heather Johnson⁵, ¹Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI, ²Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, ³Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin-Madison School of Nursing, Madison, WI, ⁵Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: The Centers for Disease Control and Prevention director has said “nothing will save more lives” than protocols to control blood pressure (BP). BP is…
Abstract Number: 1609 • 2017 ACR/ARHP Annual Meeting
Telomere Length and Coronary Artery Atherosclerosis in Patients with Systemic Lupus Erythematosus
Nathan Stein¹, Joseph F. Solus¹, Annette M. Oeser¹, Paolo Raggi², C Michael Stein¹ and Michelle J. Ormseth³, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Alberta, Edmonton, AB, Canada, ³Medicine, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Coronary atherosclerosis increases with age but is more prevalent in patients with systemic lupus erythematosus (SLE) independent of chronological age; this increased prevalence has…
Abstract Number: 2362 • 2017 ACR/ARHP Annual Meeting
Novel Biomarkers for the Prediction of Subclinical Coronary Artery Atherosclerosis in Patients with Rheumatoid Arthritis
Joan Bathon¹, Jenny Van Eyk², Nick Knowlton³, Ivan Ferraz-Amaro⁴, Jon T. Giles⁵, C. Michael Stein⁶, Mary Chester M. Wasko⁷ and Michael Centola⁸, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Advanced Clinical BioSystems Research Institute , Cedars-Sinai Medical Center, Los Angeles, CA, ³Department of Arthritis and Clinical Rheumatology, Oklahoma Medical Research Foundation, Oklahoma, OK, ⁴Rheumatology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ⁵Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁶Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁷Lupus Center, Pittsburgh, PA, ⁸Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma, OK
Background/Purpose: Cardiovascular (CV) disease risk prediction models, that were originally developed for use in the general population, have been found to have suboptimal performance in…
Abstract Number: 2937 • 2017 ACR/ARHP Annual Meeting
Genetic Variants in HLA-C and Class I Pathway Genes Influence Susceptibility to Kawasaki Disease
Chisato Shimizu¹, Jihoon Kim², Hariklia Eleftherohorinou³, Victoria Wright³, Long Hoang⁴, Adriana Tremoulet⁵, Alessandra Franco⁶, Martin Hibberd⁴, Atsushi Takahashi^7,8, Michiaki Kubo⁹, Kaoru Ito¹⁰, Toshihiro Tanaka^10,11, Yoshihiro Onouchi^10,12, Lachlan Coin³, Michael Levin³, Jane Burns¹³ and Hiroko Shike¹⁴, ¹Pediatrics, University of California San Diego, School of Medicine, La Jolla, CA, ²Medicine, University California San Diego, School of Medicine, Division of Biomedical Informatics, La Jolla, CA, ³Imperial College London, London, United Kingdom, ⁴Genome Institute of Singapore, Singapore, Singapore, ⁵Pediatrics, University California San Diego, School of Medicine, La Jolla, CA, ⁶Pediatrics, University of California San Diego School of Medicine, La Jolla, CA, ⁷Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ⁸Department of Genomic Medicine, National Cerebral And Cardiovascular Center, Suita, Japan, ⁹RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ¹⁰Laboratory for Cardiovascular Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ¹¹Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo, Japan, ¹²Department of Public Health, Chiba University Graduate School of Medicine, Chiba, Japan, ¹³Pediatrics, University California San DIego, School of Medicine, San Diego, CA, ¹⁴Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: Host genetics influence susceptibility to Kawasaki disease (KD), an acute pediatric vasculitis, and genome wide association studies (GWAS) have detected variants with modest effects…
Abstract Number: 146 • 2017 ACR/ARHP Annual Meeting
Major Cardiovascular Events Among an Inception Cohort of Seniors with Rheumatoid Arthritis
Jessica Widdifield^1,2, Michael Paterson², Anjie Huang², Bindee Kuriya³, Carter Thorne⁴, Janet E. Pope⁵ and Sasha Bernatsky⁶, ¹Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Sinai Health System, University of Toronto, Toronto, ON, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁶Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: We previously observed that incident RA patients have an increased risk of cardiovascular (CV) mortality relative to the general population in Ontario. Our aim…
Abstract Number: 1095 • 2017 ACR/ARHP Annual Meeting
Increasing Lipid Panel Monitoring in a Rheumatology Clinic
Anju Mohan¹ and Beth Scholz², ¹Internal Medicine-Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Internal Medicine - Rheumatology, University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Patients with autoimmune conditions are at increased risk for cardiovascular disease (CVD) compared to the general population. It is not routine practice at UT…

« Previous Page
1
…
7
8
9
10
11
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.